Minor timeline revision for Remygen® trial topline results
The topline results from Uppsala University Hospital’s ReGenerate-1 trial, which evaluates the safety and efficacy of Diamyd Medical's study drug Remygen[®] in individuals with Type 1 Diabetes, are expected in the first half of May 2023, reflecting a small revision to accommodate additional time required for completing statistical analyses by the contract research organization contracted by Uppsala University Hospital. The topline results will include data on endogenous insulin producing capacity measured as stimulated C-peptide and hormonal response to hypoglycemia. Additional results